CompletedNCT06213038
A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)
PHASE1 · 12 planned enrolment
- Countries listed
- 1
- Registry update
- September 11, 2026
immortal.lifeTrial registrations containing the exact intervention label SKG0106.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE1 · 12 planned enrolment
Phase not reported · 83 planned enrolment
PHASE1 · PHASE2 · 68 planned enrolment